Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’
Updated study results showed an overall response rate of 98% with a longer-term follow-up at a median of 18 months
Read More
Tag: cilta-cel
Janssen seeks EU approval for first CAR-T therapy cilta-cel
Cilta-cel is an investigational CAR-T cell therapy for the treatment of relapsed/refractory multiple myeloma
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
